Cowhide-Derived Peptide Composition for Eye Inflammation and Blue Light Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current solutions fail to effectively address eye inflammation and protection, particularly from blue light damage, and the potential decline in visual function, with limited research on the protective effects of collagen-related peptides.
Innovation Solution
A bioactive peptide with a specific amino acid sequence derived from cowhide is used to create an anti-inflammatory composition that reduces the expression of inflammation-related genes such as VEGFA, IL-1β, and IL-8, which is administered to the eyes to prevent inflammation, relieve fatigue, and protect against blue light damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If collagen-related peptides are used for eye protection, then anti-inflammatory effects may be achieved, but the specific protective effects and mechanisms remain unclear due to limited research
Solution Approach 1:
The patent synthesizes a specific collagen peptide sequence (SEQ ID NO: 1) in the laboratory to replicate and study the protective effects of naturally occurring collagen peptides from cowhide, enabling controlled research on their anti-inflammatory mechanisms without relying solely on natural extraction
Solution Approach 2:
The patent isolates a specific fragment sequence from the larger collagen protein structure to study its individual protective effects, allowing researchers to identify the precise active sequence responsible for anti-inflammatory activity rather than studying the entire collagen molecule
2Object-affected harmful factors
If blue light exposure increases due to technological products, then visual function burden increases and eye inflammation occurs, but effective protective compositions are lacking
Solution Approach 1:
The patent uses the collagen peptide as an intermediary substance that mediates protection between blue light exposure and eye tissues, where the peptide absorbs or mitigates the harmful effects of blue light before they can damage ocular cells and trigger inflammation
Solution Approach 2:
The patent applies the collagen peptide composition in advance to create a protective effect before blue light damage occurs, allowing the peptide to preemptively protect eye tissues from inflammatory responses triggered by blue light exposure
3Reliability
If inflammation-related genes are targeted for reduction, then anti-inflammatory effects are achieved, but specific effective compositions are not well-established
Solution Approach 1:
The patent optimizes the concentration parameter of the collagen peptide in the composition to achieve effective reduction of inflammation-related gene expression, determining that a concentration of at least 0.0125 mg/mL is sufficient to produce the desired therapeutic effect
Data Source
AI summary
A method for treating eye inflammation by using an anti-inflammatory composition is provided. The bioactive compound in the anti-inflammatory composition is a peptide having an amino acid sequence as set forth in SEQ ID NO.: 1. The amino acid sequence is a peptide fragment derived from cowhide. The composition may be administered to the eye of a human subject for reducing the expression of vascular endothelial growth factor A (VEGFA) gene, interleukin-1 beta (IL-1β) gene, and/or interleukin-8 (IL-8) gene.